PTEN/MMAC1/TEP1, encoding a dual-speci®city phosphatase, is a tumor suppressor gene which has recently been cloned and mapped to chromosome 10q23.3. We have shown that germline mutations of PTEN are present in individuals with two hamartoma syndromes: Cowden Syndrome, associated with a predisposition to breast and thyroid cancers, and Bannayan-Zonana syndrome. Somatic mutations of PTEN have been reported in a variety of human cancer cell lines, suggesting a potential role for this gene in the pathogenesis of human malignancies. We report the identi®cation of a highly conserved PTEN processed pseudogene, cPTEN, which shares over 98% homology with the coding region of functional PTEN, and its localisation to chromosome 9p21. The high sequence homology of cPTEN with the PTEN transcript may potentially lead to misinterpretation when performing mutation analyses based on cDNA templates. Caution should be exerted when using such screening approaches.
Keywords: MMAC1; TEP1; 9p; Cowden; pseudogene PTEN, also known as MMAC1/TEP1, has recently been cloned and mapped to chromosome sub-band 10q23.3, a region which had been previously shown to be linked to Cowden Syndrome (CS) (Li and Sun, 1997; Myers et al., 1997; Nelen et al., 1996; Steck et al., 1997) . CS is an autosomal dominant disorder associated with hamartomas of the skin, breast, thyroid, gastointestinal tract and other organs, as well as a predisposition to breast and thyroid cancers Longy and Lacombe, 1996) . We have recently shown that germline mutations of PTEN are present in individuals with CS , and also in patients with another hamartomatous disorder, Bannayan-Zonana syndrome , which shares some clinical features with CS, but without known predisposition to cancer. In addition, somatic mutations of PTEN have been reported in glioblastoma, breast, prostate and kidney cancer cell lines, suggesting it may play a role in the pathogenesis of human malignancies (Li and Sun, 1997; Steck et al., 1997) . PTEN encodes a 403-amino acid dual speci®city phosphatase, and most likely, functions as a tumor suppressor gene. Because of its apparent role in a wide variety of tumors, as preliminarily indicated by a high frequency of mutations and/or deletions in tumor cell lines, PTEN mutation analysis based on both genomic DNA and cDNA templates in several human genetic disorders as well as in primary cancers is in progress.
We identi®ed the PTEN pseudogene while characterizing PTEN transcription levels in normal and aected tissue from individuals with CS. Primers spanning the 5' and 3' untranslated regions (UTRs) of PTEN (5'-CATCTCTCTCCTCCTTTTTCTTCA-3'and R 5'-TTTTCATGGTGTTTTATCCCTCTT-3') were used for PCR with normal control genomic DNA (Promega, Madison, WI) as template. Conditions were as described previously . A 1287 bp fragment, similar in size to a product obtained with the same primers using cDNA template, was consistently ampli®ed with genomic DNA. Single-and double-stranded sequence analyses were performed as previously described . Despite using a genomic DNA template and primers which would have spanned several introns, the PCR product size obtained was that predicted for a cDNA template. Sequence analysis of this product revealed 98.6% homology to functional PTEN cDNA, with only 19 nucleotides varying from the functional PTEN cDNA sequence in a 1287 bp fragment spanning the whole coding region of the gene plus an additional 80 bp of 5' and 3' UTRs ( Figure 1 ). The lack of introns or intronlike regions in this new sequence leads us to the conclusion that this is a processed pseudogene (Vanin, 1985) . Eighteen of the 19 nucleotide dierences were found within the PTEN coding region. Most of the dierences were nucleotide transitions (79%), while only four transversion substitutions were observed ( Figure 1 ). This pattern of mutations found in cPTEN is consistent with that found in other pseudogenes, nucleotide substitutions C?T being the most commonly observed (Gojobori et al., 1982) . Although CpG dinucleotides are usually targets for mutation, only a minority (3/18) of the dierences found in cPTEN were present in such sequence context. The most noteworthy dierence observed between the two sequences was at the start codon of functional PTEN (ATG?AGG), which would preclude the use of the original PTEN open reading frame (ORF). However, a putative ORF with 369 predicted amino acids was found in cPTEN, which retains high homology with functional PTEN, including full identity with the protein tyrosine phosphatase (PTPase) motif ( Figure  2 ). The dierences observed between cPTEN and human functional PTEN were also present when the human pseudogene sequence was compared to the canine and murine functional pten (Figure 2 ), which suggests that the substitutions occurred in nucleotides that are highly conserved throughout these species.
It has been suggested that a large fraction of processed pseudogenes present in the mammalian genome have been generated by retrotransposition (Maestre et al., 1995; Vanin, 1985) . This would be mediated by transposon-encoded reverse transcriptases, followed by integration of the sequence into the genome. Unlike other mechanisms of non-processed pseudogene formation, such as genomic duplication, which results in the generation of pseudogenes in nearby sequences, integration of these reverse-transcribed sequences in the genome is more randomly distributed. Hence, the processed pseudogene is usually not syntenic with the functional gene (Vanin, 1985) .
The time of occurrence of the retrotransposition of a processed pseudogene may be tentatively estimated based on the dierences found in comparison with the coding sequence of the functional gene. If the estimated rate of *2610 79 per nucleotide per year is taken as a model ®gure for spontaneous mutation in primates (Vanin, 1985) , and if we assume that all 18 coding nucleotide dierences were accumulated by the pseudogene while the functional gene remained unchanged since their divergence, then this processed pseudogene could have originated approximately 7 million years ago. If a higher mutation rate, 4.7610 79 per nucleotide per year (Li et al., 1987) , estimated for mammals, is employed instead, the origin of the pseudogene would have been approximately 3 million years ago.
A somatic-cell hybrid panel generated using mouse and hamster backgrounds (Coriell Camden, NJ) was screened by PCR using PTEN primers (PTEN-AF 5'-AGTCCAGAGCCATTTCCATC-3' and PTEN-AR 5'-CATGGTGTTTTATCCCTCTTG-3').
Appropriate positive (human genomic DNA) and negative (mouse and hamster DNA) controls were included. cPTEN was found to map to chromosome 9. Further, a monochromosome 9 panel and a chromosome 9 radiation-hybrid panel (Research Genetics, Huntsville, AL) were PCR-screened to con®rm cOTEN chromosome mapping and better de®ne its location. The linkage likelihood data was obtained by testing the results against a Radiation Hybrid Database (SHGC, Stanford Human Genome Center). cPTEN was Figure 1 Comparison of nucleotide sequence between homologous regions of the PTEN cDNA and PTEN processed pseudogene (cPTEN). PTEN cDNA start and stop codons are underlined localized to a single interval (with a likelihood of 41000 : 1) spanning the D9S1878 marker, which lies *20 cM proximal to the p16/CDKN2 tumor suppressor gene on chromosome 9p21. Interestingly, this region, similar to the 10q23 region, where functional PTEN maps, has long been known to be frequently deleted in human cancers (Diaz et al., 1988; Einhorn and Heyman, 1993; Nobori et al., 1994) . It is possible that the 9p21 region possesses intrinsic genetic instability, allowing for more frequent alterations of genetic material to occur. In fact, a region of duplication from chromosome 7 to chromosome 9 containing several pseudogenes and genomic repeats, which appears to include cPTEN, has recently been noted (GenBank accession number AF029308).
To determine whether cPTEN was transcribed, we designed a RT ± PCR assay using a glioblastoma cell line known to be homozygously deleted for functional PTEN, A172 Steck et al., 1997) . A normal thyroid cDNA and a genomic template were used as controls. RNA was extracted using TriZol (Gibco/BRL, Paisley, UK), according to the manufacturers' instructions. Two micrograms of total RNA were reverse transcribed into cDNA using random hexamers and Superscript RNase H 7 Reverse Transcriptase (Gibco/BRL, Paisley, UK) according to the manufacturers' guidelines. PCR was performed as described above with primers spanning PTEN exons 1 to 5 (F5'-CATCTCTCTCCTCCTTTTTCTTCA-3' and R 5'-ATATCATTACACCAGTTCGTCCCT-3'), which would amplify both PTEN and cPTEN, along with primers for the house-keeping gene beta-glucuronidase (GUSB), as published (Ivanchuk et al., 1997) , at an 8 : 1 molar ratio. A product obtained with exonic PTEN primers and A172 cDNA, therefore, would represent the pseudogene. Further, to control for potential genomic DNA contamintation of the cDNA sample, cPTEN product was coampli®ed with housekeeping primers which generate a 400-bp product with a genomic DNA-based template, and a *200-bp band with cDNA templates. cPTEN primers failed to amplify the pseudogene product, while a co-ampli®ed house-keeping transcript (GUSB) showed a product of the expected size (Figure 3) . These results suggest that the pseudogene is not transcribed, at least in this glioblastoma cell line. A normal thyroid cDNA, used as a control, ampli®ed both PTEN and GUSB transcripts, while a genomic sample yielded genomic cPTEN and GUSB products. No product compatible with genomic ampli®cation was detected using the A172 template, which validated the ®nding of lack of cPTEN transcription in the model used. This is in accordance with what is usually found in other human An ethidium-bromide stained agarose gel of duplex RT ± PCR products in which PTEN primers and primers for the GUSB house-keeping gene were used at an 8 : 1 molar ratio. A normal thyroid cDNA sample ampli®ed both PTEN and GUSB transcripts, while A172, a PTEN deleted cell line, only ampli®ed the house-keeping gene band (*200 ± bp fragment). In the absence of PTEN in this template, a product of equivalent size (450 ± bp) would represent cPTEN transcript. A genomic DNA template ampli®ed both cPTEN and a 400 ± bp fragment corresponding to a genomic GUSB-related product. 100-bp ladder (Gibco, Gaithersburg, MD) was used as a size marker processed pseudogenes: due to the random nature of the transposition, processed pseudogenes are rarely in the appropriate context for transcription to occur (Vanin, 1985) . The identi®cation of a PTEN pseudogene is highly relevant for mutation detection, as PTEN is an important gene which might be involved in a wide array of inherited conditions as well as in several human cancers. The processed pseudogene, with its high homology to the functional PTEN transcript, presents the potential for misinterpretation in studies using cDNA as template for mutation detection in human disease. Due to the lack of intronic sequence, any study involving the use of exonic primers needs to be performed cautiously as many RNA preparations are not without some genomic DNA contamination. Also, the exclusive use of exonic primers in genomicbased template is potentially prone to causing misleading results in mutation studies. Hence, the possibility of the presence of cPTEN sequence has to be considered and appropriately excluded if a sequence variant is noted. Given our data, investigators wishing to use cDNA as template may now design primers in the regions relatively unique between the two sequences.
